Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K

Genetics of Pancreatic Cancer and Its Implications on Therapy

Talar Tatarian1, Jordan M Winter2

  • 1Department of Surgery, The Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University Hospital, 1015 Walnut Street, Suite 620, Philadelphia, PA 19107, USA.

The Surgical Clinics of North America
|November 21, 2016
PubMed

Insights

Emerging technologies reveal new pancreatic cancer genes but no high-frequency actionable mutations for targeted therapy. This review covers pancreas cancer genetics and current therapeutic strategies.

Area of Science:

  • Genomics
  • Oncology
  • Molecular Biology

Background:

  • Pancreatic ductal adenocarcinoma (PDA) research has advanced significantly due to new technologies.
  • Established genetic drivers like KRAS, CDKN2A, TP53, and SMAD4 are well-known in pancreatic carcinogenesis.
  • Recent studies have identified additional genes and pathways involved in PDA development.

Purpose of the Study:

  • To provide a comprehensive report on the current genetic landscape of pancreas cancer.
  • To review the status of targeted therapeutics for pancreatic ductal adenocarcinoma.
  • To highlight the challenges in identifying actionable mutations for PDA treatment.

Main Methods:

  • Review of recent scientific literature on pancreatic cancer genomics.
  • Analysis of emerging technologies and their impact on understanding PDA genetics.
  • Synthesis of data on genetic drivers and therapeutic targets in PDA.

Main Results:

  • Despite advances, no new high-frequency actionable mutations have been identified in PDA.
  • The known genetic drivers remain central to pancreatic carcinogenesis.
  • Targeted therapy success in PDA remains limited by the lack of novel, frequent mutations.

Conclusions:

  • The genomic landscape of PDA is complex and continually evolving.
  • Identifying actionable mutations is crucial for improving mutation-targeted therapy in PDA.
  • Further research is needed to discover new therapeutic strategies for pancreas cancer.
Keywords:
GeneticsPancreatic cancerPersonalized medicineTargeted therapy

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

4.1K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K